Q32 Bio files resale prospectus for up to 6.875M shares by selling stockholders from May 2026 private placement

Filed July 28, 2026 · ~1 min read

Key Changes

• high

  The prospectus covers resale of up to 6,875,000 shares, consisting of 6,725,000 common shares and 150,000 shares underlying pre-funded warrants.

  The Offering verify on EDGAR →
• high

  Q32 Bio will not receive any proceeds from the sale of shares by selling stockholders; only nominal proceeds may come from cash exercise of pre-funded warrants.

  The Offering verify on EDGAR →
• medium

  The company bears registration expenses, while selling stockholders pay underwriting discounts and commissions.

  The Offering verify on EDGAR →